Cargando…

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline

INTRODUCTION: Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting subclinical cognitiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merluzzi, Andrew P., Vogt, Nicholas M., Norton, Derek, Jonaitis, Erin, Clark, Lindsay R., Carlsson, Cynthia M., Johnson, Sterling C., Asthana, Sanjay, Blennow, Kaj, Zetterberg, Henrik, Bendlin, Barbara B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462765/ https://www.ncbi.nlm.nih.gov/pubmed/31011623 http://dx.doi.org/10.1016/j.trci.2019.02.004

Ejemplares similares

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
por: Van Hulle, Carol, et al.
Publicado: (2020)

Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum
por: Allison, Samantha L., et al.
Publicado: (2019)

Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease
por: Miners, James, et al.
Publicado: (2023)

Gut microbiome alterations in Alzheimer’s disease
por: Vogt, Nicholas M., et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis
por: Kim, Won Hwa, et al.
Publicado: (2018)

Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status
por: Gallagher, Rigina L., et al.
Publicado: (2023)

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
por: Vogt, Nicholas M., et al.
Publicado: (2018)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Measuring longitudinal cognition: Individual tests versus composites
por: Jonaitis, Erin M., et al.
Publicado: (2019)

Slowing gait speed precedes cognitive decline by several years
por: Skillbäck, Tobias, et al.
Publicado: (2022)

Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging
por: Hoy, Andrew R., et al.
Publicado: (2017)

Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum
por: Moody, Jason F., et al.
Publicado: (2022)

Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022)

Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age
por: Eren, Erden, et al.
Publicado: (2020)

Intracranial arterial four-dimensional flow is associated with metrics of brain health and Alzheimer's disease
por: Berman, Sara E., et al.
Publicado: (2015)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Tau as a fluid biomarker of concussion and neurodegeneration
por: Hossain, Iftakher, et al.
Publicado: (2022)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age
por: Betthauser, Tobey J, et al.
Publicado: (2020)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease
por: Picard, Cynthia, et al.
Publicado: (2021)

CSF T-Tau/Aβ(42) Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease
por: Bendlin, Barbara B., et al.
Publicado: (2012)

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2023)

The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
por: Johnson, Sterling C., et al.
Publicado: (2017)

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2022)

METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research
Publicado: (2016)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

The decline of domiciliary dentistry
por: Emanuel, Robert, et al.
Publicado: (2021)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2023)

Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2023)

Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals
por: Xu, Yuexuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gtog724542qp0iolih6scji5b3